ArticleCancer immunology, immunotherapy : CII2008
Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Tunable CAR-NK-92 activity in the tumor microenvironment via a dual ATF4-responsive circuit.Frontiers in immunology · 2026Article
- Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing.bioRxiv : the preprint server for biology · 2025Article
- Article
- Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy.RNA nanomed · 2025Article
- Down-Regulation of HLA-C Expression on Melanocytes May Contribute to the Therapeutic Efficacy of UVB Phototherapy in Psoriasis.International journal of molecular sciences · 2025Article
- Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.Cancer immunology, immunotherapy : CII · 2023Article
- Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages.Cancer immunology, immunotherapy : CII · 2023Article
- Review
- The immune-related role of beta-2-microglobulin in melanoma.Frontiers in oncology · 2022Review
- Article
- Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.Frontiers in immunology · 2021Review
- Review
- Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti-PD-1 monoclonal antibody.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019Article
- Adaptive Resistance to Cancer Immunotherapy.Advances in experimental medicine and biology · 2017Review
- Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma.Nature communications · 2016Article
- Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor GrowthFrontiers in pharmacology · 2016Article
- Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance.Cancer immunology, immunotherapy : CII · 2016Article
- Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer.Cancer immunology, immunotherapy : CII · 2013Article
- Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies.Pigment cell & melanoma research · 2013Article
- Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.Transfusion · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAltered HLA class I cell surface expression is one of the major mechanisms by which tumor cells escape from T lymphocytes. Immunohistochemistry-defined phenotypes of lost HLA class I expression have been described in human solid tumors, nut less information is available on melanoma cell lines.
objectivesTo describe the frequency and distribution of different types of HLA class I antigen alterations in 91 melanoma cell lines from the European Searchable Tumour Cell and Databank (ESTDAB).
methodsThe HLA class I expression was assessed by flow cytometry and HLA genotyping.
resultsWe found various types of HLA class I cell surface alterations in about 67% of the melanoma cell lines. These alterations range from total to selective HLA class I loss due to loss of heterozygosity (LOH), haplotype loss, beta2-microglobulin gene mutation, and/or total or selective down-regulation of HLA class I molecules. The most frequently observed phenotype is down-regulation of HLA-B locus that was reversible after treatment with IFN -gamma.
conclusionsIn general, HLA class I alterations in the majority of the cells analyzed were of regulatory nature and could be restored by IFN-gamma. Analysis of the frequency of distinct HLA class I altered phenotypes in these melanoma cell lines revealed specific differences compared to other types of tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.